Joint American Academy of Dermatology & National Psoriasis Foundation New Care Guidelines for Medication Management of Psoriasis Waltham, MA – August 12, 2020 – press release Echosens, a high-technology company…
Read More
JUNE 12, 2020: COLLABORATION, BEST PRACTICES AND EARLY DETECTION OF FATTY LIVER DISEASE June 8th, 2020, Published in Business Wire Echosens, a high-technology company offering the FibroScan family of products, joins…
Echosens urges increased vigilance around liver health during May 2020 Hepatitis Awareness Month and calls attention to the millions of Americans from all walks of life who are living with the most common causes of viral hepatitis: hepatitis B virus (HBV) and hepatitis C virus (HCV).
Expanding Patient-Centered Care for Chronic Liver Conditions: Gastroenterology Specialists Improve Outcomes, Lower Costs & Enhance Practice Performance March 31, 2020, Published in Business Wire Echosens, proudly announces its collaboration with…
Echosens shares a mission with the Fatty Liver Foundation to reach into every community in America to ensure asymptomatic individuals receive the screening and care they need.
Echosens proudly announces the publication of the “FibroScan-AST (FAST) Score in The Lancet Gastroenterology & Hepatology.
Echosens aligns with the Fatty Liver Foundation to accelerate screening for undiagnosed NAFLD-NASH patients.
Echosens calls for increased vigilance by healthcare providers to monitor liver health at the point of care, address obesity, diabetes and halt progression of NAFLD.
Echosens will provide a live demonstration of a FibroScan examination, in partnership with Fidelis, at the Department of Veterans Affairs’ (VA) National Veterans Small Business Engagement
FAST is a cost-effective tool to help identify individuals at risk for fibrotic NASH, an asymptomatic progressive liver disease that leads to increased liver-related mortality and morbidity.
